Financial conflicts of interest among oncology clinical pathway vendors

JAMA Oncology

Volumn 4, Issue 2, 2018, Pages 255-257

  Daly, Bobby ^a   Bach, Peter B ^a   Page, Ray D ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Center for Cancer and Blood Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; PANITUMUMAB;

CLINICAL PATHWAY; COLORECTAL CANCER; CONFLICT OF INTEREST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; LETTER; MEDICAL FEE; ONCOLOGY; PRESCRIPTION; COMMERCIAL PHENOMENA; DRUG INDUSTRY; ECONOMICS; ETHICS; HEALTH CARE; HUMAN; INTENSIVE CARE; MEDICAID; MEDICAL ETHICS; MEDICARE; NEOPLASM; ORGANIZATION AND MANAGEMENT; PROCEDURES; STANDARDS; UNITED STATES;

COMMERCE; COMPREHENSIVE HEALTH CARE; CONFLICT OF INTEREST; CRITICAL CARE; CRITICAL PATHWAYS; DRUG INDUSTRY; ETHICS, PHARMACY; HUMANS; MEDICAID; MEDICAL ONCOLOGY; MEDICARE; NEOPLASMS; UNITED STATES;

EID: 85047012982     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.4473     Document Type: Letter

References (6)

1. Ellis PG, O'Neil BH, Earle MF, et al. Clinical pathways: management of quality and cost in oncology networks in the metastatic colorectal cancer setting. J Oncol Pract. 2017;13(5):e522-e529.
2. Schroeder A. Clinical pathways: a current snapshot, and the journey ahead. J Clin Pathways. 2017;3(2):33-40.
3. Carlson RW,McClure JS. Financial relationships with industry among National Comprehensive Cancer Center Network guideline authors. JAMA Oncol. 2016;2 (12):1660.
4. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006;355(16):1640-1642.
5. Oncology Clinical Pathways Act of 2017, AB 1107, California Assembly Committee on Health (April 2017).
6. Institute of Medicine. Conflict of Interest in Medical Research, Education, and Practice.Washington, DC: National Academies Press; 2009.